Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Julie Cooke Sells 700 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 700 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $118.28, for a total value of $82,796.00. Following the transaction, the insider now directly owns 18,831 shares in the company, valued at $2,227,330.68. This trade represents a 3.58 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Julie Cooke also recently made the following trade(s):

• On Friday, January 31st, Julie Cooke sold 1,740 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $152.89, for a total value of $266,028.60.

Neurocrine Biosciences Stock Up 0.3 %

NASDAQ NBIX opened at $117.18 on Thursday. The firm has a 50-day moving average price of $138.49 and a two-hundred day moving average price of $131.02. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The company has a market capitalization of $11.86 billion, a P/E ratio of 35.62 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. Equities analysts expect that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on NBIX shares. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Morgan Stanley upped their target price on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Wedbush reduced their price target on Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Royal Bank of Canada lowered their price target on Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a research report on Friday, February 7th. Finally, UBS Group raised their price objective on Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $166.90.

Institutional Trading of Neurocrine Biosciences

Institutional investors have recently modified their holdings of the stock. Caprock Group LLC bought a new position in shares of Neurocrine Biosciences in the fourth quarter worth $236,000. Plato Investment Management Ltd grew its stake in Neurocrine Biosciences by 2,481.9% during the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after buying an additional 10,548 shares in the last quarter. Swiss National Bank increased its holdings in Neurocrine Biosciences by 1.4% in the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after buying an additional 4,100 shares during the period. Tri Ri Asset Management Corp acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $3,236,000. Finally, KBC Group NV lifted its holdings in shares of Neurocrine Biosciences by 78.3% during the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after acquiring an additional 8,332 shares during the period. 92.59% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.